Drug Profile

WSK V102

Alternative Names: WSK-V102

Latest Information Update: 14 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Westvac Biopharma
Class COVID-19 vaccines; Synthetic vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I COVID 2019 infections

Most Recent Events

01 Mar 2023 Westvac Biopharma plans a phase I trial in COVID-2019 infection (Prevention) in March 2023 (IM) (NCT05765604)
26 Aug 2021 Westvac Biopharma announces intention to submit NDA for Unspecified indication (Prevention) in China in Q3 2022
26 Aug 2021 Westvac Biopharma announces intention to submit IND for Unspecified indication (Prevention) in Q2 of 2021

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com